Krystal beats; Europe weighed by German pricing accruals
Krystal Biotech beats Q2 2026 EPS estimates on strong VYJUVEK revenue of $119.2M, Europe weighed by German pricing accruals
- Investor Takeaway: Strong U.S. VYJUVEK growth and profitability; Europe optics skewed by German pricing accruals.
- Key Results: Q2 revenue $119.2m (+24% YoY); U.S. $91.6m; EPS $1.79 diluted.
- Guidance & Outlook: 2026 non-GAAP R&D+SG&A $175–195m maintained; registrational readouts expected 2026–2027.
- Growth Drivers: U.S. VYJUVEK penetration >60% diagnosed DEB; 730+ reimbursements; strong community-setting demand.
- Problem Areas: Europe/Japan revenue flat QoQ from German price reserves despite underlying vial growth.
- Margins & Profitability: Gross margin 95% vs 93% prior-year; net income $54.8m.
- Notable Items: Cash and investments exceed $1.1b; no capital return changes disclosed.
- Key Metrics: Over 180 international patients treated; 35–50 new U.S. approvals quarterly.
- Management Tone: Confident on global VYJUVEK ramp, HSV-1 platform, oncology; acknowledges ex-U.S. launch complexities.
- Q&A Focus: Germany pricing, Europe demand, NK and CF trial design, NK market sizing.
- Main concern: European revenue volatility and ultimate economics amid ongoing German pricing negotiations.
- Strong quarter, driven by robust U.S. VYJUVEK growth and high gross margins.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.